alacizumab pegol
mAbexperimental
Alacizumab pegol is an antineoplastic agent. Chemically, it is a pegylated F(ab')2 fragment of a monoclonal antibody. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2005 (NCT00152477)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
KDR antagonist
CDP791 binds specifically to VEGFR-2, inhibiting activation by its ligands VEGF-A, VEGF-C, VEGF-D and therefore, blocking all signaling through this receptor.
KDR inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAlacizumab pegol ↗
- ChEMBLCHEMBL1742983 ↗
Also known as
- alacizumab pegol
- cdp791
- cdp-791
- g165 dfm-peg
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00152477 | Phase 2 | Aug 1, 2005 | Hoosier Cancer Research Network |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hoosier Cancer Research Network | Academic/Hospital | 1 | 1 | 1 | 2005 |
1 organizations
Page 1 / 1